SG3 Management’s Immunovant IMVT Stock Holding History

SG3 Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,500	Closed	-$34.9K	–	1163
2021 Q1	$40K	Buy	+2,500	New	+$65.9K	﹤0.01%	1099

Other funds holding IMVT

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's IMVT Position: Q2 2021 in Review

SG3 Management sold out of Immunovant (IMVT) in Q2 2021, closing a stake of 2,500 shares — an estimated $34.9K sold.

SG3 Management first reported a position in IMVT in Q1 2021 and held it in 1 quarter. The position peaked at $40K in Q1 2021. 110 funds tracked by Wall St. Rank hold IMVT as of Q2 2021.

SG3 Management reported no remaining Immunovant position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 2,500 Immunovant shares in Q2 2021, an estimated $34.9K.
SG3 Management first reported a position in Immunovant in Q1 2021 and held it in 1 quarter.
SG3 Management's Immunovant position peaked at $40K in Q1 2021.
110 funds tracked by Wall St. Rank held Immunovant as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.